Ritu Lal

This inventor holds 14 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Gen1e Lifesciences Inc., Genie Lifesciences Inc., Leland Stanford Junior University. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ritu Lal. Retrieved from https://idiyas.com/inventor/ritu-lal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 8)

% Patents Active = 92.9

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 32(Granted Patents)

Company Filing History:

10 out of 10

Gen1e Lifesciences Inc.

patents

2 out of 2

Genie Lifesciences Inc.

patents

2 out of 5,512

Leland Stanford Junior University

patents

4. 1 out of 2,027

University System of Maryland

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753184 - P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS (2026-10-06),

2. 12595243 - Modulators of extracellular signal-regulated kinase (2026-04-07),

3. 12404259 - Inhibitors of extracellular signal-regulated kinase (2025-09-02),

4. 12331024 - Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors (2025-06-17),

5. 12269792 - Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate (2025-04-08),

6. 12116353 - Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt (2024-10-15),

7. 11976049 - Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors (2024-05-07),

8. 11926635 - P38α mitogen-activated protein kinase inhibitors (2024-03-12),

9. 11555020 - Substituted naphthyl p38α mitogen-activated protein kinase inhibitors (2023-01-17),

10. 11440918 - p38α mitogen-activated protein kinase inhibitors (2022-09-13),

11. 11390581 - Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate (2022-07-19),

12. 11286260 - P38α mitogen-activated protein kinase inhibitors (2022-03-29),

13. 11191667 - Method and system for regulating core body temperature (2021-12-07),

14. 9956113 - Method and system for regulating core body temperature (2018-05-01),

Title: Ritu Lal: Innovator in Pharmaceutical Sciences

Introduction

Ritu Lal is a prominent inventor based in Palo Alto, CA (US). He has made significant contributions to the field of pharmaceutical sciences, holding a total of 14 patents. His work focuses on developing innovative compounds for treating various diseases, particularly cancer and pulmonary conditions.

Latest Patents

Among his latest patents, Ritu has developed inhibitors of extracellular signal-regulated kinase. This includes the compound 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate, along with pharmaceutical compositions for its use in treating cancer and pulmonary diseases. Additionally, he has worked on substituted naphthyl p38α mitogen-activated protein kinase inhibitors, which also include pharmaceutical compositions aimed at treating various diseases.

Career Highlights

Ritu has had a notable career, working with esteemed organizations such as Gen1e Lifesciences Inc. and Leland Stanford Junior University. His innovative research and development efforts have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Ritu has collaborated with talented individuals in his field, including Adam Galan and Wendy Luo, who is a woman. These collaborations have further enhanced his research and contributions to pharmaceutical sciences.

Conclusion

Ritu Lal's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.